AR042450A1 - Indazolilpirrolotriazinas modificadas c-6 - Google Patents
Indazolilpirrolotriazinas modificadas c-6Info
- Publication number
- AR042450A1 AR042450A1 ARP030104592A ARP030104592A AR042450A1 AR 042450 A1 AR042450 A1 AR 042450A1 AR P030104592 A ARP030104592 A AR P030104592A AR P030104592 A ARP030104592 A AR P030104592A AR 042450 A1 AR042450 A1 AR 042450A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- heterocycle
- aryl
- alkyl
- group
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 6
- 125000003107 substituted aryl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 2
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 abstract 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 abstract 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 abstract 1
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Inks, Pencil-Leads, Or Crayons (AREA)
Abstract
La presente proporciona compuestos de la fórmula (1), en donde: R se selecciona del grupo que consiste de arilo, arilo sustituido, heterociclo, y heterociclo sustituido; R1 se selecciona del grupo que consiste de alquilo y alquilo sustituido; R2 se selecciona del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido; o, R2 puede estar ausente; X se selecciona del grupo que consiste de un enlace, O, S, C(R3)2, C(R3)3, NR3; y N(R3)2; R3 se selecciona independientemente del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido y sales, profármacos, enantiómeros, diastereómeros, y solvatos farmacéuticamente aceptables del mismo. Los compuestos de la fórmula (1) inhiben la actividad de la tirosina cinasa de los receptores del factor de crecimiento tales como HER1, HER2 y HER4 por lo que son útiles como agentes antiproliferativos para cáncer, psicosis y artritis reumatoidea. Estos compuestos también son útiles para el tratamiento de otras enfermedades asociadas con las trayectorias de transducción de senal, que operan a través de los receptores del factor de crecimiento. Composición farmacéutica que comprende los compuestos de la fórmula (1) junto a un portador farmacológicamente aceptable. Reivindicación 1: Un compuestos de la fórmula (1), en donde: R se selecciona del grupo que consiste de arilo, arilo sustituido, heterociclo, y heterociclo sustituido; R1 se selecciona del grupo que consiste de alquilo y alquilo sustituido; R2 se selecciona del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido; o, R2 puede estar ausente; X se selecciona del grupo que consiste de un enlace, O, S, C(R3)2, C(R3)3, NR3; y N(R3)2; R3 se selecciona independientemente del grupo que consiste de hidrógeno, alquilo, alquilo sustituido, arilo, arilo sustituido, aralquilo, heterociclo, y heterociclo sustituido y sales, profármacos, enantiómeros, diastereómeros, y solvatos farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43319002P | 2002-12-13 | 2002-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042450A1 true AR042450A1 (es) | 2005-06-22 |
Family
ID=32595133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104592A AR042450A1 (es) | 2002-12-13 | 2003-12-12 | Indazolilpirrolotriazinas modificadas c-6 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6916815B2 (es) |
| EP (1) | EP1569937B1 (es) |
| JP (1) | JP4511367B2 (es) |
| KR (1) | KR101073801B1 (es) |
| CN (2) | CN1726216A (es) |
| AR (1) | AR042450A1 (es) |
| AT (1) | ATE534648T1 (es) |
| AU (1) | AU2003300877B2 (es) |
| BR (1) | BR0316755A (es) |
| CA (1) | CA2509650C (es) |
| CO (1) | CO5570660A2 (es) |
| DK (1) | DK1569937T3 (es) |
| ES (1) | ES2374393T3 (es) |
| HR (1) | HRP20050535A2 (es) |
| IS (1) | IS7890A (es) |
| MX (1) | MXPA05006164A (es) |
| NO (1) | NO20052733L (es) |
| NZ (1) | NZ540338A (es) |
| PE (1) | PE20040805A1 (es) |
| PL (1) | PL377517A1 (es) |
| PT (1) | PT1569937E (es) |
| RS (1) | RS20050441A (es) |
| RU (1) | RU2356903C2 (es) |
| TW (1) | TW200420565A (es) |
| UA (1) | UA80591C2 (es) |
| WO (1) | WO2004054514A2 (es) |
| ZA (1) | ZA200504507B (es) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2273083C (en) * | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| US7393823B1 (en) | 1999-01-20 | 2008-07-01 | Oregon Health And Science University | HER-2 binding antagonists |
| US7625859B1 (en) | 2000-02-16 | 2009-12-01 | Oregon Health & Science University | HER-2 binding antagonists |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
| AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| TW200306841A (en) | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| PT1506203E (pt) | 2002-08-23 | 2007-04-30 | Sloan Kettering Inst Cancer | Síntese de epotilonas, seus intermediários, seus análogos e suas utilizações |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| JP2006516653A (ja) | 2003-02-05 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤ピロロトリアジンの製造方法 |
| ES2428358T3 (es) * | 2003-10-17 | 2013-11-07 | Novo Nordisk A/S | Terapia de combinación |
| US7102001B2 (en) * | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| US20060014741A1 (en) * | 2003-12-12 | 2006-01-19 | Dimarco John D | Synthetic process, and crystalline forms of a pyrrolotriazine compound |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7064203B2 (en) * | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| US7459562B2 (en) | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7102002B2 (en) * | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US20050288290A1 (en) | 2004-06-28 | 2005-12-29 | Borzilleri Robert M | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7439246B2 (en) | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7253167B2 (en) * | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| US7102003B2 (en) * | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
| CA2583230A1 (en) * | 2004-10-05 | 2006-04-20 | Oregon Health And Science University | Compositions and methods for treating disease |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| WO2006111524A2 (en) * | 2005-04-18 | 2006-10-26 | Novo Nordisk A/S | Il-21 variants |
| US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7402582B2 (en) * | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US7514435B2 (en) * | 2005-11-18 | 2009-04-07 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7348325B2 (en) | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| KR20080107408A (ko) | 2006-03-07 | 2008-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물 |
| EP2091968A2 (en) | 2006-10-26 | 2009-08-26 | Novo Nordisk A/S | Il-21 variants |
| JP2010512769A (ja) * | 2006-12-21 | 2010-04-30 | ノヴォ ノルディスク アクティーゼルスカブ | Ｉｌ−２１受容体との結合が変化したインターロイキン−２１変異体 |
| US20090083483A1 (en) * | 2007-09-24 | 2009-03-26 | International Business Machines Corporation | Power Conservation In A RAID Array |
| US8166326B2 (en) * | 2007-11-08 | 2012-04-24 | International Business Machines Corporation | Managing power consumption in a computer |
| US20090132842A1 (en) * | 2007-11-15 | 2009-05-21 | International Business Machines Corporation | Managing Computer Power Consumption In A Computer Equipment Rack |
| US8041521B2 (en) * | 2007-11-28 | 2011-10-18 | International Business Machines Corporation | Estimating power consumption of computing components configured in a computing system |
| WO2009137201A1 (en) | 2008-04-04 | 2009-11-12 | Cv Therapeutics, Inc. | Triazolopyridinone derivatives for use as stearoyl coa desaturase inhibitors |
| WO2009124259A1 (en) * | 2008-04-04 | 2009-10-08 | Cv Therapeutics, Inc. | Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors |
| US20110086850A1 (en) * | 2008-04-11 | 2011-04-14 | Board Of Regents, The University Of Texas System | Radiosensitization of tumors with indazolpyrrolotriazines for radiotherapy |
| US8103884B2 (en) | 2008-06-25 | 2012-01-24 | International Business Machines Corporation | Managing power consumption of a computer |
| US8041976B2 (en) * | 2008-10-01 | 2011-10-18 | International Business Machines Corporation | Power management for clusters of computers |
| US8514215B2 (en) * | 2008-11-12 | 2013-08-20 | International Business Machines Corporation | Dynamically managing power consumption of a computer with graphics adapter configurations |
| WO2010071885A1 (en) | 2008-12-19 | 2010-06-24 | Cephalon, Inc. | Pyrrolotriazines as alk and jak2 inhibitors |
| MX2011009413A (es) * | 2009-03-11 | 2011-10-21 | Ambit Biosciences Corp | Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer. |
| WO2011112689A2 (en) * | 2010-03-11 | 2011-09-15 | Ambit Biosciences Corp. | Saltz of an indazolylpyrrolotriazine |
| US9724352B2 (en) | 2012-05-31 | 2017-08-08 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pyrrolo[2,1-F[1,2,4]triazine compounds, preparation methods and applications thereof |
| CN103450204B (zh) | 2012-05-31 | 2016-08-17 | 中国科学院上海药物研究所 | 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途 |
| JP6386527B2 (ja) * | 2013-03-11 | 2018-09-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | カリウムイオンチャネル阻害剤としてのピロロピリダジン |
| US9050345B2 (en) * | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| CN105026399B (zh) * | 2013-03-11 | 2017-06-23 | 百时美施贵宝公司 | 作为钾离子通道抑制剂的吡咯并三嗪类化合物 |
| WO2015081783A1 (zh) * | 2013-12-06 | 2015-06-11 | 江苏奥赛康药业股份有限公司 | 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途 |
| CN111533708B (zh) * | 2020-06-12 | 2021-03-16 | 上海馨远医药科技有限公司 | 一种手性n-叔丁氧羰基吗啉-3-羧酸的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4908056A (en) * | 1986-04-25 | 1990-03-13 | E. I. Du Pont De Nemours And Company | Heterocyclic acyl sulfonamides |
| EP0778277B1 (en) | 1995-12-08 | 2003-06-25 | Pfizer Inc. | Substituted heterocyclic derivatives as CRF antagonists |
| JP3621706B2 (ja) | 1996-08-28 | 2005-02-16 | ファイザー・インク | 置換された６，５―ヘテロ―二環式誘導体 |
| KR100666514B1 (ko) * | 1999-05-21 | 2007-02-28 | 브리스톨-마이어즈 스퀴브 컴페니 | 키나제의 피롤로트리아진 저해제 |
| US6787545B1 (en) | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| GEP20063915B (en) * | 2000-11-17 | 2006-09-11 | Bristol Myers Squibb Co | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS |
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| TW200306841A (en) | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| AU2003231034B2 (en) | 2002-04-23 | 2009-03-05 | Bristol-Myers Squibb Company | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| TWI329112B (en) | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| US7102001B2 (en) * | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
-
2003
- 2003-12-08 TW TW092134601A patent/TW200420565A/zh unknown
- 2003-12-12 AU AU2003300877A patent/AU2003300877B2/en not_active Ceased
- 2003-12-12 BR BR0316755-0A patent/BR0316755A/pt not_active IP Right Cessation
- 2003-12-12 EP EP03813396A patent/EP1569937B1/en not_active Expired - Lifetime
- 2003-12-12 WO PCT/US2003/039542 patent/WO2004054514A2/en not_active Ceased
- 2003-12-12 JP JP2004560804A patent/JP4511367B2/ja not_active Expired - Fee Related
- 2003-12-12 RS YUP-2005/0441A patent/RS20050441A/sr unknown
- 2003-12-12 AT AT03813396T patent/ATE534648T1/de active
- 2003-12-12 PL PL377517A patent/PL377517A1/pl not_active Application Discontinuation
- 2003-12-12 UA UAA200506891A patent/UA80591C2/uk unknown
- 2003-12-12 RU RU2005120650/04A patent/RU2356903C2/ru not_active IP Right Cessation
- 2003-12-12 HR HR20050535A patent/HRP20050535A2/hr not_active Application Discontinuation
- 2003-12-12 KR KR1020057010549A patent/KR101073801B1/ko not_active Expired - Fee Related
- 2003-12-12 CN CNA200380105906XA patent/CN1726216A/zh active Pending
- 2003-12-12 ES ES03813396T patent/ES2374393T3/es not_active Expired - Lifetime
- 2003-12-12 CA CA002509650A patent/CA2509650C/en not_active Expired - Fee Related
- 2003-12-12 CN CN200910246410A patent/CN101723948A/zh active Pending
- 2003-12-12 DK DK03813396.3T patent/DK1569937T3/da active
- 2003-12-12 PE PE2003001275A patent/PE20040805A1/es not_active Application Discontinuation
- 2003-12-12 AR ARP030104592A patent/AR042450A1/es unknown
- 2003-12-12 PT PT03813396T patent/PT1569937E/pt unknown
- 2003-12-12 MX MXPA05006164A patent/MXPA05006164A/es active IP Right Grant
- 2003-12-12 NZ NZ540338A patent/NZ540338A/en not_active IP Right Cessation
- 2003-12-15 US US10/736,476 patent/US6916815B2/en not_active Expired - Fee Related
-
2005
- 2005-06-01 ZA ZA200504507A patent/ZA200504507B/en unknown
- 2005-06-02 US US11/143,279 patent/US7148220B2/en not_active Expired - Fee Related
- 2005-06-07 NO NO20052733A patent/NO20052733L/no not_active Application Discontinuation
- 2005-06-10 IS IS7890A patent/IS7890A/is unknown
- 2005-06-13 CO CO05057043A patent/CO5570660A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042450A1 (es) | Indazolilpirrolotriazinas modificadas c-6 | |
| AR037368A1 (es) | Imidazolilpirrolotriazinas c-5 modificadas y composiciones farmaceuticas que las comprenden | |
| AR040272A1 (es) | Inhibidores heterociclicos de cinasas | |
| PE20220592A1 (es) | Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos | |
| BR0314965A (pt) | Derivados de 2-oxodiidropiridina n-substituìdos | |
| ES2111896T3 (es) | Aminocompuestos sustituidos, su preparacion y metodos de tratamiento. | |
| BR0312801A (pt) | inibidores de azaindol cinase | |
| JP7595004B2 (ja) | 甲状腺ホルモン受容体ベータアゴニスト化合物 | |
| UY26086A1 (es) | Procedimientos e intermedios para preparar compuestos anticancerosos | |
| UY26872A1 (es) | Derivados de la 4- fenil piridina | |
| UY27225A1 (es) | Inhibidores de la rho-quinasa | |
| CY1118723T1 (el) | Ενωσεις βενζοθειαζολιου και αζαβενζοθειαζολιου χρησιμες ως αναστολεiς κινασης | |
| ES2571779T3 (es) | Inhibidores de cinasa a base de nicotinamida | |
| AR060562A1 (es) | Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas. | |
| BRPI0418231A (pt) | compostos de pirrolotriazina como inibidores da cinase | |
| UY24482A1 (es) | Quinoxalinadionas | |
| BRPI0509307A (pt) | compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1 | |
| PT1261602E (pt) | Derivados imidazol-2-carboxamida como inibidores de cinase raf | |
| ATE240328T1 (de) | Substituierte azaoxindolederivate | |
| BR112012014807A2 (pt) | "compostos adequados para o tratamento de sinucleopatias" | |
| TW200519096A (en) | Quinazoline analogs as receptor tyrosine kinase inhibitors | |
| RU2005113153A (ru) | Новые пиримидинамидные производные и их применение | |
| WO2021222138A1 (en) | Compounds for mutant ras protein degradation | |
| PE20252677A1 (es) | Amidas de azolipiridina piridazinona como inhibidores de sos1 | |
| BRPI0411414A (pt) | derivados de quinolil amida como antagonistas de cdr-5 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |